Immuneering Corp (IMRX) Form 10-Q — May 15, 2026
Immuneering Corp reported a net loss of $13.5 million for the quarter ended March 31, 2026, driven by $10.6 million in R&D expenses and $4.7 million in G&A expenses. The company holds $198.6 million in total liquidity (cash and marketable securities), which management estimates is sufficient to fund operations into 2029. The filer confirmed it is recruiting for the MAPKeeper 301 Phase 3 trial of atebimetinib in pancreatic cancer, with first patient dosing expected in mid-2026. No new equity was sold during the quarter, though the company retains $98.7 million in capacity under its ATM program.
Key figures
- Total Debt
- 0
- Total Assets
- 214809790
- Cash Position
- 47321566
- Shares Outstanding
- 64697402
- Ga Expense
- 4682495
- Rd Expense
- 10645222
- Cash Burn Operating
- 18433444
Price after filing
Close on the filing date to close N calendar days later (from $5.14). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.